IMMUNE THROMBOCYTOPENIC PURPURA (ITP)
Clinical trials for IMMUNE THROMBOCYTOPENIC PURPURA (ITP) explained in plain language.
Never miss a new study
Get alerted when new IMMUNE THROMBOCYTOPENIC PURPURA (ITP) trials appear
Sign up with your email to follow new studies for IMMUNE THROMBOCYTOPENIC PURPURA (ITP), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New shot could help ITP patients avoid bleeding emergencies
Disease control Recruiting nowThis study tests a drug called mezagitamab, given as a shot under the skin, in adults with chronic immune thrombocytopenia (ITP) — a condition where the immune system destroys platelets needed for clotting. The goal is to see if the drug can keep platelet counts stable over 6 mon…
Matched conditions: IMMUNE THROMBOCYTOPENIC PURPURA (ITP)
Phase: PHASE3 • Sponsor: Takeda • Aim: Disease control
Last updated May 26, 2026 11:36 UTC
-
New drug hopes to raise platelet counts in teens with chronic bleeding disorder
Disease control Recruiting nowThis study tests an IV drug called efgartigimod in teens aged 12 to 18 who have had immune thrombocytopenia (ITP) for over a year. ITP causes low platelet counts, leading to bruising and bleeding. The goal is to find the right dose and see if it safely raises platelet levels. Par…
Matched conditions: IMMUNE THROMBOCYTOPENIC PURPURA (ITP)
Phase: PHASE2, PHASE3 • Sponsor: argenx • Aim: Disease control
Last updated May 26, 2026 11:33 UTC
-
New shot shows promise for Long-Term control of bleeding disorder
Disease control Recruiting nowThis study tests the long-term safety of a drug called mezagitamab for adults with chronic immune thrombocytopenia (ITP), a condition where the immune system destroys platelets, causing easy bruising and bleeding. About 150 participants who were in earlier mezagitamab studies wil…
Matched conditions: IMMUNE THROMBOCYTOPENIC PURPURA (ITP)
Phase: PHASE3 • Sponsor: Takeda • Aim: Disease control
Last updated May 18, 2026 12:09 UTC